USC scientists create a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable
USC researchers have developed a polio vaccine that doesn’t require refrigeration, meaning it could someday be used all over the world to deliver the final blow to this longtime foe.
The vaccine, which was freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice.
Stabilization is not rocket science, so most academics don’t pay much attention to this field.
Woo-Jin Shin
“Stabilization is not rocket science, so most academics don’t pay much attention to this field,” said the study’s first author, Woo-Jin Shin, a fellow in the lab of Jae Jung, chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC. “However, no matter how wonderful a drug or vaccine is, if it isn’t stable enough to be transported, it doesn’t do anyone much good.”
The study appears in the Nov. 27 issue of the journal mBio.
Polio is on the brink of complete eradication, with just 22 reported cases worldwide in 2017. The highly infectious disease, which causes lifelong paralysis and disability mostly in young children, is a fading memory in many places. Yet in countries where vaccination rates are spotty, young children are at risk.
The biggest hitch to complete eradication has been creating a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable. Recent polio cases have been reported in Nigeria, Papua New Guinea, Syria and Pakistan.
Other freeze-dried vaccines
In the United States, the polio epidemic reached its height in the 1950s. In 1957, mass immunization brought the annual number of cases down from 58,000 to 5,600. Since 1979, no cases of polio have originated in the United States.
By removing moisture through freeze-drying, researchers have created temperature-stable vaccines for measles, typhoid and meningococcal disease. But scientists haven’t been able to make a polio vaccine that retains potency through freeze-drying and rehydration.
Shin and his colleagues used two lab techniques — liquid chromatography and high-throughput screening — that allowed them to analyze a high volume of ingredients and formulations until they found one that worked.
Jung’s hope is that a foundation or company will take over the project to pay for human studies and bring the injectable vaccine onto the market.
In addition to Shin, the study’s authors are Daiki Hara and Jae Jung of the Keck School of Medicine, and Francisca Gbormittah, Hana Chang and Byeong S. Chang of Integrity Bio, a company that specializes in biologics — medicines made from substances found in living things.
Back story: During dinner three years ago, Jung and his college buddy Chang, CEO of Integrity Bio, decided to bring together Jung’s virology expertise with Chang’s expertise in stabilization. Chang paid Shin’s salary, and Jung provided supplies.
“He and I decided to do this as we are getting old and we need to directly contribute to human health and life,” Jung said. “Creative ideas always start with food and drinks.”
Learn more: Vaccine breakthrough brings researchers closer to eliminating polio worldwide
The Latest on: Temperature-stable vaccine
[google_news title=”” keyword=”temperature-stable vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Temperature-stable vaccine
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africaon April 26, 2024 at 10:30 pm
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Soligenix extends patent protection for its filovirus vaccine platform to the UK and South Africaon April 26, 2024 at 5:49 am
Soligenix announced it has received notice of intent to grant additional patents based on its patent application in the UK and South Africa.
- Nature Publication Highlights the Benefits of Tropis® Intradermal When Used to Administer a First-in-Class Self-Amplifying mRNA Vaccineon April 24, 2024 at 7:10 am
Nature study shows delivery of a novel self-amplifying mRNA-based vaccine with Tropis directly into the dermis significantly boosts immune responses.
- World Health Organization approves updated cholera vaccine to combat surge in caseson April 19, 2024 at 3:57 am
The World Health Organization has approved a new version of a cholera vaccine that could help address a surge in cases that has depleted the global vaccine stockpile.
- IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101on April 18, 2024 at 6:03 am
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarterLAWRENCEVILLE, N.J., ...
- The Temperature Controlled Pharmaceutical Container Market Value to Reach US$ 7.7 Billion by 2034 End | Future Market Insights Inc.on April 17, 2024 at 10:30 am
Temperature Controlled Container Use has Increased Significantly in the Pharmaceutical Sector. United States temperature controlled pharmaceutical container market grows at 2.9% CAGR till 2034. NEWARK ...
- Soligenix bags orpan drug designation for Marburg virus vaccineon April 15, 2024 at 11:49 am
The US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax, Soligenix’s vaccine for the prevention and post-exposure prophylaxis against Marburg ...
- Soligenix Granted Orphan Drug Designation for Vaccine to Treat MARV Infectionon April 15, 2024 at 10:12 am
Soligenix, Inc. announced that the Office of Orphan Products Development of the FDA has granted orphan drug status ...
- SOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infectionon April 15, 2024 at 6:30 am
Provides MarVax Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon ... Stability studies have demonstrated that MarVax is heat stable for at least 2 years at temperatures of at least 40 ...
via Bing News